Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
Stocks · News reference
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Monte Rosa Therapeutics, Inc. (GLUE)
Filed: 2026-10-01 AccNo: 0001193125-26-409833 Size: 21 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.